|
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 17939/22958 (78%)
Visitors : 7383252
Online Users : 111
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/22199
|
Title: | Metabolic Syndrome Prevalence and Cardiovascular Risk Assessment in HIV-Positive Men with and without Antiretroviral Therapy |
Authors: | Lu, Win-Long;Lee, Yuan-Ti;Sheu, Gwo-Tarng |
Contributors: | 中山醫學大學;醫研所 |
Keywords: | HIV;cardiovascular disease;metabolic syndrome;HAART;Framingham risk score |
Date: | 2021-06-05 |
Issue Date: | 2022-03-29T03:00:09Z (UTC)
|
Publisher: | MDPI |
Abstract: | Treatment of HIV infection is a lifelong process and associated with chronic diseases. We evaluated the prevalence and predictors of metabolic syndrome (MetS) and cardiovascular diseases (CVDs) with individual antiretroviral drugs exposure among HIV-infected men in Taiwan. A total of 200 patients’ data were collected with a mean age of 32.9. Among them, those who had CD4 positive cell number less than 350/mL were eligible to have highly active antiretroviral therapy (HAART). Patients were divided into group-1 that contains 45 treatment-naïve participants, and group-2 that includes 155 HAART treatment-experienced participants. MetS prevalence between group-1 and group-2 was 18% and 31%, respectively. The Framingham Risk Score (FRS) for the naïve and experienced groups were 4.7 ± 4.2 and 3.87 ± 5.92, respectively. High triglyceride (TG > 150 mg/dL) in group-1 and group-2 were 15.6% and 36.6% (p < 0.05), whereas, lower high-density lipoprotein (HDL < 39 mg/dL) in group-1 and group-2 presented as 76.7% versus 51% (p < 0.05), respectively. In group-2, treatment with protease inhibitors (PIs) resulted in higher TG levels when compared with non-nucleotide reverse transcriptase inhibitors (NNRTIs) and integrase inhibitors (InSTIs). The prevalence of MetS in the treatment-naïve group was lower than that of the treatment-experienced group; high TG level resulted in higher MetS prevalence in the treatment-experienced group. In contrast, the cardiovascular risk of FRS in the treatment-naïve group was higher than that of the treatment-experienced group, which may result from the low HDL level. Although group-1 participants have a higher risk of developing CVDs, in group-2, an increasing TG level in PIs user indicated higher CVDs risk. TG and HDL are two significant biofactors that required regular evaluation in HIV-positive individuals. |
URI: | https://ir.csmu.edu.tw:8080/handle/310902500/22199 |
Relation: | Medicina,Volume 57,Issue 6 ,10.3390 |
Appears in Collections: | [醫學研究所] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
medicina-57-00578.pdf | | 319Kb | Adobe PDF | 115 | View/Open |
|
All items in CSMUIR are protected by copyright, with all rights reserved.
|